Companies
7 companies with in-depth analysis
ARGX
argenx SE
✓ Detailed
No description available
$51BMarket Cap
HIGH
ARWR
Arrowhead Pharmaceuticals
✓ Detailed
RNAi platform with extra-hepatic delivery (TRiM). 1 approved (REDEMPLO), 3 Phase 3
$8.6BMarket Cap
HIGH
ASND
Ascendis Pharma
✓ Detailed
No description available
$13.6BMarket Cap
HIGH
EWTX
Edgewise Therapeutics
✓ Detailed
No description available
$3.2BMarket Cap
HIGH
KYMR
Kymera Therapeutics
✓ Detailed
No description available
$6.0BMarket Cap
HIGH
NUVL
Nuvalent
✓ Detailed
No description available
$7.3BMarket Cap
HIGH
ARDX
Ardelyx
✓ Detailed
Commercial-stage GI/nephrology. IBSRELA (IBS-C, 92% YoY growth), XPHOZAH (hyperphosphatemia). NHE3 platform.
$1.7BMarket Cap
MEDIUM
Want access to 180+ more companies? Email us to gain full access